Browse Articles
Discover research articles across all indexed journals
Strong interface coupling for enhanced photoresponse in 1D BiInSe/2D WSe2 phototransistor
With the improvement of heterostructure preparation technology, research on the physical properties and device performance of mixed-dimensional heterostructures has been greatly developed. Numerous studies have focused on 2D/2D heterostructures, but research on 1D/2D heterostructures is comparatively limited, and the interface electron transfer mechanism needs to be further explored. In this study, we leverage the inherent band structure alignment characteristics of 1D Bi1.3In0.7Se3 and 2D WSe2 to create Bi1.3In0.7Se3/WSe2 heterostructure with Type-I band alignment. The results of PL, Raman, and KPFM prove the existence of a strong coupling effect at the heterostructure interface. The Bi1.3In0.7Se3 nanowire enhances the PL intensity and red-shifts the PL peaks of WSe2. This strong local electric field at the heterojunction interface improves the photoresponse performance of the Bi1.3In0.7Se3/WSe2 heterostructures devices. They achieve excellent photoresponce properties in a wide spectral range from solar-blind ultraviolet C (254 nm) to near-infrared (980 nm) region, with a large responsivity of 98 A/W, a high detectivity of 1.16 × 1013 Jones, and a fast photoresponse time of 500 μs. In addition, the optoelectronic performance of the device is controlled by modulating the Fermi level of the heterostructure by the applied gate electric field. Our work paves the way for the development of 1D/2D heterostructures for multifunctional optoelectronic applications.
Reconstruction of porous media pore structure and simulation effect analysis of multi-index based on SNESIM algorithm
Abstract The pore structure of porous media directly affects its permeability characteristics and fluid flow properties, making the accurate reconstruction of these structures of great significance. In recent years, multi-point statistics (MPS) methods have been widely used in pore structure modeling. Among them, the SNESIM algorithm, as an advanced MPS technique, has been extensively applied in the study of porous media pore structures. This paper aims to investigate the use of the SNESIM algorithm for reconstructing pore structures on 2D core slices with varying porosities, all taken from the same core. It also analyzes the effectiveness, limitations, and applicable conditions of the algorithm. This study utilizes CT scan images to construct digital core technology and applies the SNESIM algorithm to reconstruct pore structures of core slices with different porosities. By analyzing performance parameters such as porosity, pore throat ratio, average grain radius, coordination number, and permeability, the study shows that the reconstructed images(RI) from most samples maintain a trend similar to that of the training images(TI), demonstrating the good applicability and reliability of the SNESIM algorithm in pore structure reconstruction. However, the core slices used in this study were all taken from the same core. Effectively transferring the pore structures from the 2D plane to the 3D pore space and restoring the pore structures to the greatest extent still requires further research. In particular, when dealing with complex pore structures, the accuracy and performance of the SNESIM algorithm need further improvement. Future research will focus on optimizing the algorithm to handle more diverse pore structures and exploring 3D reconstruction methods to more comprehensively describe and analyze the pore characteristics in actual porous media.
Optimizing clear cell renal cell carcinoma tumor-infiltrating lymphocytes under controlled hypoxic conditions.
581 Background: Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) represents a promising approach for advanced solid tumor treatment. Historically, the success of TIL therapy in clear cell renal cell carcinoma (ccRCC) has been limited by difficulty expanding cytotoxic functional TILs. Hypoxic conditions in the ccRCC tumor microenvironment have been associated with mixed tumor characteristics, including metabolic dysregulation and tumor progression. Given the significant role of hypoxia in ccRCC progression, we investigated TIL expansion under controlled hypoxic conditions and its impact on TIL cytotoxic functions. Methods: Fragments or tumor digests from 41 ccRCC patients were cultured with high-dose (6000IU/mL) IL-2 for four weeks. TIL expansion success was defined as at least one fragment expanding to a minimum of 2 wells. Primary TIL underwent rapid expansion protocol (REP) at 20% (normoxic) or 5% (hypoxic) O 2 levels. Cells were rested in post-REP media for 3–4 days in their respective conditions (20% or 5% O 2 ) and subsequently collected for downstream analysis. Reactivity to autologous tumor, expression of activation/co-inhibitory markers, and memory phenotype were analyzed with flow cytometry and co-culture assays. Results: TILs were successfully grown in 87.8% of samples (36/41). TILs secreted IFNγ in response to autologous tumors in 88.6% (31/35) of the samples. Both TIL expansion and reactivity occurred independently of tumor stage or grade. TIL REP under hypoxic conditions (5% O2) was successful, and these conditions salvaged more CD8+ TILs compared to normoxic conditions (p=0.0382). Hypoxic REP TILs showed increased IFNγ, TNFα, and Granzyme B release in response to autologous tumor compared to normoxic conditions. Additionally, hypoxic REP TILs expressed higher LAG3 and TIM3 markers (p<0.05), with significantly increased proportions of tissue-resident memory-like (TRM) CD8+ T-cells (CD69+CD103+) compared to normoxic conditions (18.2% CD69+CD103+ versus 2.6%, respectively, p<0.0001). These features have been associated with clinical responders TILs in melanoma. Conclusions: This study demonstrates the feasibility of expanding tumor-reactive TILs from ccRCC despite tumors harboring exhausted CD8+ T-cells. Exposing TILs to hypoxic conditions enhanced effector functions and promoted the acquisition of a TRM T-cell phenotype. These findings suggest that ccRCC TIL expansion under controlled hypoxia is feasible and could confer improvement to the clinical efficacy of TIL therapy for ccRCC.
Prognostic significance of tumor immune microenvironment dynamics in prostate cancer induced by androgen deprivation therapy.
398 Background: The dynamics of the prostate cancer microenvironment through androgen regulation are unclear. In this study, we analyzed the relationship between the dynamics of the immune microenvironment and prognosis after androgen deprivation therapy. Methods: We retrospectively reviewed the patients who underwent radical prostatectomy at our institution. Among them, 104 patients received prostate needle biopsy and neoadjuvant androgen deprivation therapy at the same institution. These cases were compared before and after androgen deprivation therapy. Immune cell infiltration in the cancer areas was assessed using multiplex fluorescent immunohistochemistry. Transcriptome analysis and gene panel analysis by next-generation sequencing were used to systematically and comprehensively analyze the expression and mechanisms of the immune microenvironment. Results: Few immune cells were detected in the needle biopsies before androgen deprivation therapy. After androgen deprivation therapy, prostatectomy specimens showed a significant change in various immune cells, including CD4 + T cells, CD8 + T cells, Foxp3 + regulatory T cells, CD204 + macrophages, and CD20 + B cells (P< 0.001). In particular, CD8 + T cells and CD20 + B cells were significantly increased compared to patients who did not receive androgen deprivation therapy followed by total prostatectomy (P<0.001). Clustering analysis allowed stratification into three groups: One group had a predominant increase in CD8 + T cells after androgen deprivation therapy, another group had a predominant increase in CD20 + B cells, and the third group had no significant increase. The group with increased CD8 + T cells had a significantly higher 5-year biochemical recurrence rate of 56 % (P=0.045). Differences in the mechanisms of androgen metabolism were observed among these cases. Conclusions: Differences in immune induction after androgen deprivation therapy have an impact on the prognosis of prostate cancer.
Clinicopathological characteristics of cancer of unknown primary (CUP) with renal profile using gene expression profiling (GEP) based cancer classification.
456 Background: CUP is a rare and heterogenous clinicopathologic syndrome with unidentifiable origin at time of diagnosis. Based on immunophenotyping, specifically PAX8 staining, CUP with Renal profile (RCUP) is emerging as a distinct clinical subset. In addition to clinical presentation and immunohistochemistry (IHC), molecular profiling for tissue of origin may aid defining CUP subsets. Precision in diagnosis impacts therapeutics given that cytotoxic chemotherapy options for CUP do not overlap with tyrosine kinase inhibitors or checkpoint inhibitors used for renal cell carcinoma. Methods: We retrospectively (2018-2022) evaluated patients with CUP composed of cases (renal profile, N=100, clear cell or papillary) or controls (non-renal, N=200) identified using the 92-gene assay (CancerTYPE ID), a validated classifier for predicting tissue of origin. Clinicopathologic data including IHC and molecular profiling results were collected using pathology specimens and reports. Results: Baseline characteristics (age, gender, tumor grade) of cases and controls were comparable, except for histology, wherein adenocarcinoma was less common with RCUP (27% vs 48%, p<0.001). Median number of IHC stains performed was 11 (range 0-30) vs 9 (0-29) (p=0.04) in RCUP vs non-renal cases, respectively. While PAX8 was tested in 64% vs 39% (p<0.001) of cases, it was found to be strongly or focally positive in 87.5% vs 21.8% (p<0.001), respectively. In contrast to non-renal CUP, RCUP patients were more likely to have bone biopsies (24% vs 11.5%, OR 2.4, p=0.007), less likely to have high-TMB (2.8% vs 28.2%, OR 0.07, p=0.001), and had a lower proportion of TP53 mutations (18.8% vs 89.2%, OR 0.028, p<0.001), KRAS mutations (13.3% vs 77.4%, OR 0.045, p<0.001) and BRAF mutations (0% vs 42%, OR 0, p=0.015). Conclusions: RCUP appears to be a distinct subset of CUP with variable diagnostic workup. Critical IHC markers may be omitted in a considerable number of cases and despite positivity, may still confer an uncertain diagnosis. Key molecular factors appear to be different and may require tailored therapeutic approaches. This study further supports the clinical utility of GEP-based cancer classification with the 92-gene assay to predict RCUP and may be an important adjunct to IHC to improve diagnostic accuracy for CUP and to guide treatment selection for better clinical outcomes. RCUP (N=100) Non-renal CUP (N=200) IHC Cases Tested (%) Cases Positive (%) Cases Tested (%) Cases Positive (%) CK7 83 47 81 75* CK20 75 11 77 24* PAX8 64* 88* 39 22 Napsin 29 28* 25 8 RCC 26* 31 4 13 Vimentin 17 94 5.5 73 *Significantly (p<0.05) greater proportion of cases.
An open-label phase 1, window-of-opportunity study of ultrasound-guided long acting periprostatic neuraxial block with ethanol in patients with high-risk prostate cancer.
391 Background: Patients (pts) with high-risk prostate cancer (PCa) have an elevated risk of disease recurrence/progression after definitive therapy. These pts also exhibit increased levels of adrenergic nerve density on PCa histology. Pre-clinical evidence from murine models of PCa suggest that PCaNeurolysis of periprostatic adrenergic nerves inhibits cancer progression and metastasis by inhibiting angiogenesis, altering cancer metabolism, and inhibiting cell migration (PMC5783182). Pure Ethanol (>99%) injection for neurolysis is FDA-approved in chronic cancer pain and may have a survival benefit in late-stage cancers (PMC1242819). Ultrasound-guided (US) short-acting periprostatic neuraxial block with lidocaine is commonplace in urologic practice. Thus, PCaNeurolysis with ethanol may have both a protective effect in high risk PCa and be feasibly implemented. Methods: Pts with NCCN high risk PCa who were interested and eligible for surgery, and who did not have any prior PCa treatments received in-office US guided PCaNeurolysis with either 3mL or 5mL of pure ethanol 4 to 6 weeks prior to radical prostatectomy (surgery was not delayed for trial participation). Dose escalation was determined by keyboard design with 6 pts per group (dose limiting toxicity [DLT] period = 6 weeks; DLT ³ Grade 3 events). Results: Dose escalation: 12 pts, median age 68, were treated at 2 dose levels: 3/5mL (n=6/6) with no DLTs in either group, suggesting 5mL was maximal tolerated dose to use in future studies. Additionally, no off-target effects including no decrease in erectile function (Sexual Health Inventory for Men score), no increase in urinary symptoms (International Prostate Symptom Score), and no added difficulty (eg. Destruction of tissue planes) during prostatectomy were observed in any pts. 7 pts underwent prostatectomy (43% cT3a) and were included in secondary analysis: median decrease in adrenergic density on final pathology (35%), ≥pT3a (0%), 18month biochemical recurrence (14%). Conclusions: PCaNeurolysis with ethanol was well tolerated, and 5mL was the maximum tolerated dose to use in future studies. Histologically significant decrease in adrenergic nerve density was observed suggesting the intervention acts upon its intended target, and the intervention may have antitumor activity (43% pre-injection cT3a, but 0% ≥pT3a on final pathology after injection). These Phase 1 results encourage continued investigation of PCaNeurolysis in high risk PCa pts.
Heterostructure and interfacial engineering for low-resistance contacts to ultra-wide bandgap AlGaN
We report on the heterostructure and interfacial engineering of metalorganic chemical vapor deposition (MOCVD) grown reverse graded contacts to ultra-wide bandgap AlGaN. A record low contact resistivity of 1.4 × 10−6 Ω cm2 was reported on an Al0.82Ga0.18N metal-semiconductor field effect transistor by compositionally grading the contact layer from Al0.85Ga0.15N → Al0.14Ga0.86N with degenerate doping and proper interfacial engineering considering bandgap-narrowing-induced band offset between the channel and the contact layer. This represents orders-of-magnitude of lower contact resistivity than that obtained in similar MOCVD-grown structures. A detailed, layer-by-layer analysis of the reverse graded contact and TCAD simulation of the bandgap narrowing effect highlighted that the reverse graded contact layer itself is extremely conductive, and interfacial resistance due to bandgap-narrowing-induced barrier between contact and channel dominates the contact resistance.
Metabolomic profile of severe COVID-19 and a signature predictive of progression towards severe disease status: a prospective cohort study (METCOVID)
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.
LBA18 Background: The Phase 3 TALAPRO-2 trial met its primary endpoint, showing improved radiographic progression-free survival (rPFS) for TALA + ENZA vs placebo (PBO) + ENZA as 1L treatment in pts with mCRPC unselected for homologous recombination repair (HRR) gene alterations (all-comers; cohort 1). Here we report final OS data, a descriptive update of rPFS, and extended safety follow-up in cohort 1. Methods: In cohort 1, pts were randomized 1:1 to ENZA 160 mg + either TALA 0.5 mg (0.35 mg if moderate renal impairment) or PBO once daily and stratified by prior abiraterone or docetaxel (yes/no) for castration-sensitive PC and HRR gene alteration status. Key eligibility criteria included asymptomatic or mildly symptomatic mCRPC, ECOG PS ≤1, ongoing androgen deprivation therapy, and no prior life-prolonging therapy for CRPC. The primary endpoint was rPFS by blinded independent central review. OS was an alpha-protected key secondary endpoint. For statistical significance at the final OS analysis, the stratified log-rank 2-sided P value needed to be ≤0.022 using a group sequential design with O’Brien-Fleming spending function. Results: Overall, 805 pts were randomized, 402 to TALA+ENZA and 403 to PBO+ENZA. At data cutoff (Sept 3, 2024), 211 pts (52%) in the TALA + ENZA arm and 243 pts (60%) in the PBO + ENZA arm had died; median follow-up was 52.5 and 53.0 months, respectively. Hazard ratio (HR) for OS with TALA + ENZA vs PBO + ENZA was 0.796 (95% CI, 0.661–0.958; 2-sided P =0.0155); median OS (95% CI), 45.8 months (39.4–50.8) vs 37.0 months (34.1–40.4 months), respectively. In prespecified subgroup analyses, OS favored TALA + ENZA vs PBO + ENZA in pts who were HRR-deficient (n=169; HR, 0.549; 95% CI, 0.364–0.826; P =0.0035) or HRR–non-deficient/unknown (n=636; HR, 0.878; 95% CI, 0.713–1.080; P =0.218). In exploratory analyses of pts with results available for both circulating tumor DNA and tumor tissue, OS favored TALA + ENZA vs PBO + ENZA in pts without BRCA1/2 alterations (n=439; HR, 0.749; 95% CI, 0.582–0.963; P =0.024) and in pts without HRR alterations (n=314; HR, 0.782; 95% CI, 0.582–1.050; P=0.101). Consistent with the primary analysis, updated rPFS data favored TALA + ENZA vs PBO + ENZA (HR, 0.667; 95% CI, 0.551–0.807; P <0.0001); median rPFS, 33.1 vs 19.5 months, respectively. Consistent with primary results, the most common grade ≥3 TEAEs with TALA + ENZA were anemia (49%) and neutropenia (19%). TEAEs were generally manageable; 86 pts (22%) discontinued TALA due to TEAEs. Conclusions: TALA + ENZA demonstrated a statistically significant and clinically meaningful improvement in OS vs standard-of-care ENZA as 1L treatment in pts with mCRPC unselected for HRR gene alterations. rPFS continued to favor TALA + ENZA. No new safety signals were identified with extended follow-up. Clinical trial information: NCT03395197 .
Evaluating the impact of a community-based prostate cancer screening program.
324 Background: One out of eight men in the U.S. will be diagnosed with prostate cancer during his lifetime. Early detection, often by routine screening, allows for more options for treatment and an increased chance of survival. Barriers to screening exist and may contribute to prostate cancer disparities, particularly among Black males and those who lack regular access to health care. Community based screening programs may be an effective way to overcome barriers to prostate cancer screening. Methods: An urban, NCI-designated cancer center collaborated with community partners and a national prostate cancer advocacy organization to provide free screening to males in our catchment area. Community partners identified the location of the screening and promoted the event. Participants completed a survey about their personal and family history of prostate cancer. A mobile screening team within the cancer center conducted the screenings, consisting of prostate specific antigen (PSA) tests. All participants received a letter with their PSA test results; males with an abnormal result (> 3 ng/mL) also received a phone call. Survey data was analyzed with descriptive statistics and bivariate analyses (ANOVA). Results: Two hundred and eighty-nine (n=289) males were screened at a community screening event. The mean age of males screened was 57.3 (SD=11.2) and the majority identified as Black (N=253, 84.9%). The mean PSA test value was 1.82 (SD= 2.70); 14% of males had an abnormal PSA test result. Black males had the highest PSA values of among all men who were screened. Conclusions: Disparities in prostate cancer, particularly among Black males, warrant interventions like community-based prostate screening events that reduce barriers of cost and access, bringing screening to those who would most benefit. Mean PSA test results by patient characteristics. N Mean PSA Level Sum of Squares, DF Between Groups Within Groups F p Full Sample 298 1.82 Race/Ethnicity 3; 19.62 271; 1876.18 0.94 0.42 Black 246 1.85 Hispanic 18 0.80 White 9 1.48 Other 2 1.59 PSA in the last 3 years, # tests 3; 19.43 260; 1861.65 0.91 0.44 0 121 1.62 1-3 133 1.82 4-6 6 3.40 7+ 4 2.08 Family history of PCa, # of relatives 2; 54.09 287; 2051.72 3.78 0.024* 0 215 1.78 1 63 1.50 2+ 12 3.84 Family history of PCa genetic risk, # of relatives 2; 11.75 287; 2094.06 0.81 0.45 0 229 1.71 1 52 2.24 2+ 10 1.96 Smoking status 4; 31.74 256; 1815.53 1.12 0.35 Current 26 2.19 Former, quit within 10 years 8 0.93 Former, quit within 11-19 years 8 1.46 Former, quit more than 20 years ago 20 2.75 Never 199 1.68 Diet, fat intake 2; 9.49 272; 1888.09 0.68 0.51 Low 60 1.65 Medium 186 1.71 High 29 2.29 Chemical Exposure 1; 2.80 257; 1824.87 0.39 0.53 Not exposed 210 1.72 Exposed 49 1.97 *Indicates significance (p <0.05).
Reply to: Peak Corticosteroid Dose for Immune-Related Adverse Events and Survival: Not the Whole Story
Survival impact of concomitant squamous differentiation in upper tract urothelial carcinoma patients receiving adjuvant chemotherapy.
729 Background: Adjuvant platinum-based chemotherapy after radical nephroureterectomy (RNU) was a strong recommendation for patients with pT2–4 and/or pN+ upper tract urothelial carcinoma (UTUC). However, the efficacy of adjuvant chemotherapy (AC) on UTUC with squamous differentiation (UTUCSD) remains unclear. This study was conducted to investigate survival impact of SD on UTUC patients receiving AC, and further assessed the efficacy of AC on UTUCSD. Methods: Data of 868 UTUC patients who underwent RNU at West China Hospital of Sichuan University from May 2003 to June 2021 were retrospectively included, and only patients with the history of postoperative adjuvant chemotherapy were further analyzed. The end points included overall survival (OS), cancer-specific survival (CSS) and metastasis-free survival (MFS). Propensity score matching (PSM), Kaplan‒Meier curves and Cox proportional hazard model were utilized. Results: Overall, the prevalence rate of UTUCSD is 10.7% (93/868), and UTUCSD significantly tended to be locally advanced (pT>2), high grade and lymph node metastasis (LNM) disease. After PSM for tumor stage, grade, and LNM, 32 paired cohorts at a ratio of 1 to 3 among patients received chemotherapy (according to the presence/absence of SD) were derived. Compared with pure UTUC patients receiving AC, UTUCSD patients showed significantly inferior OS (HR 1.99, 95% CI 1.06-3.71) and CSS (HR 1.95, 95% CI 1.09-3.47) but comparable MFS (HR 1.33, 95% CI 1.0.71-2.50). Furthermore, AC could not bring significant survival benefit to patients with UTUCSD in terms of OS (HR 0.73, 95% CI 0.40-1.31) and CSS (HR 0.88, 95% CI 0.46-1.69). Conclusions: Concomitant SD acted as an inferior survival predictor among UTUC patients receiving AC. UTUCSD is less sensitive to chemotherapy and effective treatments need to be further studied.
Al2O3/<i>in situ</i> GaON gate dielectrics incorporated GaN MIS-HEMTs with stable VTH and significantly reduced interface state density
This work reports a metal–insulator–semiconductor High-Electron-Mobility-Transistor (HEMT) with Al2O3/in situ GaON bi-layer gate dielectric for improved threshold voltage (VTH) stability and reduced interface state density. With a combination of in situ GaON and large bandgap Al2O3 on top of the recessed gate region, normally-off HEMT was achieved with high On/Off current (ION/IOFF) ratio of 109, low VTH hysteresis less than 60 mV, and low-interface trap density (Dit) in the range of 4 × 1011–2 × 1012 cm−2·eV−1. Thanks to the sharp GaN/oxide interface with narrow distribution of lattice constant, uniform strain distribution and significantly reduced trap density were obtained. More importantly, our proposed bi-layer gate dielectric is perfectly compatible with the conventionally utilized gate recessing technique compared to the conventionally utilized in situ SiNx, demonstrating itself as a promising candidate in GaN power devices.
Impact of the eastern Tibetan Plateau on the ecological sensitivity of the West Qinling Mountains
Body composition and immunotherapy outcomes in patients with advanced urothelial carcinoma.
762 Background: Abnormalities in body composition, including sarcopenia and myosteatosis, have been identified as prognostic factors in patients (pts) receiving cytotoxic chemotherapy. However, data regarding the impact of these factors in patients undergoing immune checkpoint inhibitors (ICI) therapy, particularly in those with advanced urothelial carcinoma (aUC), remain limited. This study aimed to evaluate the prognostic significance of body compositions obtained from abdomen-pelvis computed tomography (APCT) in pts with aUC. Methods: This retrospective study included pts with aUC who received ICI (atezolizumab or pembrolizumab) between Jan 2019 and Dec 2022 at Asan Medical Center, Seoul, Korea. Body composition was evaluated using selected axial images at the L3 lumbar vertebrae level from APCT, through an artificial intelligence-driven imaging analysis platform. T-score ≤-2 (-2 SD from the mean reference value in Korean population) was used as cutoff points for sarcopenia and myosteatosis. Visceral obesity (VO) was defined as visceral fat area ≥ 100cm 2 and subcutaneous obesity (SFO) as subcutaneous fat area / height 2 ≥ 50cm 2 /m 2 in males and 42cm 2 /m 2 in females. The associations between body composition parameters with overall survival (OS) and progression-free survival (PFS) were analyzed. Results: A total of 212 pts were included. Median age was 68 (range, 31-86) and 53 pts (25%) were females. ICIs were primarily administered as second-line treatment following failure to platinum-based treatment (N=207, 98%), with 5 pts (2%) receiving ICI as first-line treatment in a metastatic setting. Atezolizumab was given to 174 pts (82%) and pembrolizumab to 38 pts (18%). The prevalence of sarcopenia prior to treatment was 22% (45/212), while myosteatosis was observed in 52% of pts (110/212). VO and SFO were present in 62% and 43% of pts, respectively, with 37% classified as overweight (body mass index (BMI) ≥25kg/m 2 ). Myosteatosis at baseline was associated with an increased risk of mortality (HR 1.58, 95% CI: 1.11–2.23), while sarcopenia, VO, SFO, and BMI did not show significant associations with OS. PFS was not affected by any body composition parameters. Multivariate Cox regression analysis demonstrated that liver metastasis (HR 2.78, 95% CI: 1.94–4.00), hemoglobin (HR 0.52, 95% CI 0.35-0.77), and myosteatosis (HR 1.57, 95% CI 1.12-2.19) were independently associated with OS after adjusting for age and sex. Conclusions: In pts with aUC treated with ICI, myosteatosis showed poorer OS, while sarcopenia, VO, SFO, and BMI did not demonstrate a significant impact. Myosteatosis was significantly associated with OS after adjusting for other clinical factors, which suggests a possibility of a novel prognostic marker in pts with aUC receiving ICI.
Assessing molecular heterogeneity of prostate cancer biopsy sampling: Insights from the MAST trial.
240 Background: Prostate cancer is heterogeneous and multi-focal, and biopsy sampling often undersamples the tumor or samples different tumor foci. Such heterogeneity can lead to inaccurate molecular classifications of tumor biology on tissue-based prognostic tests. Consequently, this impacts treatment decision making and management in localized prostate cancer. Herein, we evaluate the degree of variability in transcriptomic profiles when assessing genomic profiles from MRI-guided versus template biopsy using the Decipher GRID platform. Methods: A total of 205 men enrolled in the Miami MRI selection for Active Surveillance versus Treatment (MAST) trial (NCT02242773), from which 408 biopsy samples from 159 patients with successful genomic profiling were used in this study. Across the whole time-course, all biopsy cores with successful gene expression profiling were categorized by mpMRI-targeted (149 samples) or template (259 samples) sampling. Three main prognostic signatures (Decipher genomic classifier DGC, derived cell cycle progression CCP, and derived Genomic Prostate score GPS) were used to assess the variation in genomic risk between MRI targeted and template cores and among different PI-RADS lesions. Similar analysis was performed in a selected cohort with Gleason grade 1 disease only to exclude the impact of grade on genomic risk assessment. Results: Using the main genomic signatures in unpaired analysis (comparing all targeted and template biopsies), targeted lesions had higher scores as compared to the random biopsies, except for Decipher score (p=0.105). However, in the paired analysis (only including targets and templates from the same patient), we saw no difference between the groups in all three of the signatures. In the subset of patients with GG1, there was no difference between random and targeted biopsies in paired analysis. Among MRI targeted biopsy cores, PI-RADS level was correlated to Decipher and CCP scores with higher PI-RADS levels resulting in higher genomic scores (p=0.007 and 0.002, respectively). However, when restricting to a subgroup of patients with only GG1 cancer, there was no longer an association between PIRADS and genomic score. Higher concordance of DGC scores between visible and non-visible lesions were observed in the low-risk group. Conclusions: mpMRI sampling showed higher genomic scores compared to template sampling. While we see an association between higher PI-RADS scores and higher genomic scores, this relationship appeared to be driven by grade. Among the subgroup of men with GG1 cores, we found no association between PI-RADS and genomic scores. These findings need further validation in a larger cohort to truly understand the impact of MRI targeting on genomic risk assessment among AS patients. Clinical trial information: NCT02242773 .
Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease–associated tumors: Results of LITESPARK-015 study.
534 Background: Pts with VHL disease are at risk of developing malignant tumors such as renal cell carcinoma (RCC) due to VHL gene inactivation, leading to activation of hypoxia-inducible factors (HIFs). In the phase 2 LITESPARK-004 study, HIF-2α inhibitor belzutifan (MK-6482) demonstrated antitumor activity and a manageable safety profile in pts with VHL disease–associated tumors; however, the study did not include pts from Asia. We present results for pts from mainland China with VHL disease–associated localized tumors enrolled in cohort B1 of the phase 2, open-label, single-arm LITESPARK-015 study (NCT04924075). Methods: Eligible pts were aged ≥18 yrs with localized VHL disease–associated tumors diagnosed by local germline testing and/or clinically (per family history and ≥1 VHL-related tumor, ≥2 retinal/central nervous system [CNS]-hemangioblastomas [HBs], or 1 retinal/CNS-HB and ≥1 VHL-related visceral tumor [except renal/epididymal cysts]), and with ≥1 measurable pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), or RCC per RECIST v1.1 by blinded independent central review (BICR) not requiring immediate surgery. Pts received belzutifan 120 mg orally QD until PD or unacceptable toxicity. A primary endpoint for cohort B1 was ORR per RECIST v1.1 by BICR in VHL disease–associated RCC in patients from China. Secondary endpoints included disease control rate (DCR), time to response (TTR), duration of response (DOR), PFS (BICR), OS, and safety. Results: 23 pts from China enrolled and treated in cohort B1 had ≥1 primary tumor: RCC, n=18; CNS-HB (solid component), n=7; CNS-HB (solid + cystic components), n=10; pNET, n=12; and PPGL, n=4. Median study follow-up was 14.9 (range, 12.0–17.1) months at data cutoff (May 23, 2024). ORR in pts with RCC was 83% (95% CI, 59%–96%); 15 pts achieved PR. All 4 pts with PPGL had SD. Additional data are shown in the Table. No PFS or OS events had occurred. All-cause AEs occurred in all 23 pts (100%), most commonly (incidence ≥20%) anemia, ALT increased, AST increased, asthenia, URI, and GGT increased. Grade 3 AEs occurred in 9 pts (39%; no grade 4–5), serious AEs in 3 pts (13%). AEs that led to treatment discontinuation occurred in 1 pt (treatment-related tumor hemorrhage of kidney). Conclusions: Belzutifan showed a favorable benefit/risk profile for VHL disease–associated localized tumors in pts from China, with a clinically meaningful response rate, durable responses, and manageable safety profile. Clinical trial information: NCT04924075 . RCCN = 18 a CNS-HB (Solid)N = 7 a CNS-HB (Solid + Cystic)N = 10 a pNETN = 12 a ORR (95% CI), % 83(59–96) 100(59–100) 60(26–88) 67(35–90) DCR (95% CI), % 100(82–100) 100(59–100) 100(69–100) 100(74–100) TTR, median (range), mo 5.6(2.7–11.1) 2.8(2.6–3.0) 2.9(2.6–5.6) 5.6(2.5–8.4) DOR, median (range), mo NR(2.7+ to 11.1+) NR(8.1+ to 14.1+) NR(5.6+ to 14.1+) NR(2.8+ to 11.3+) a Pts may have had ≥1 primary tumor type.
Sensitive tissue-based detection of AR-V7 and other androgen receptor alterations using combined DNA/RNA comprehensive genomic profiling.
195 Background: Mechanisms of resistance to agents targeting the androgen receptor (AR) axis in prostate cancer (PC) include AR amplification (AMP), ligand-binding domain mutations (MUT), and splice variants (AR-Vs), such as AR-V7, which has been associated with resistance to the AR signaling inhibitors (ARSi) abiraterone and enzalutamide in castration resistant PC (CRPC). Clinically employed AR-V7 assays involve detection in circulating tumor cells (CTCs) based on either nuclear protein immunofluorescent staining or RNA expression. We sought to define the AR landscape of PC using DNA and RNA comprehensive genomic profiling (CGP) of tissue biopsies (TBx). Methods: We queried an institutional database (Foundation Medicine, Inc.) of CGP results. DNA and RNA co-extracted from formalin fixed paraffin embedded (FFPE) tumor TBx were profiled, respectively, using FoundationOne CDx (F1CDx) and FoundationOne RNA (F1RNA). AR-V7 positivity was defined by the presence of ≥10 unambiguous supporting reads in RNA. In DNA, AMP was defined as an amplification ratio of the modeled gene copy number to sample ploidy of ≥3. Results: 94% (51/54) of PC FFPE samples underwent successful F1CDx + F1RNA, while 3 of 54 had inadequate RNA. The most commonly altered genes were AR (51.9%), PTEN (37.0%), ERG (25.9%), TP53 (24.1%) and SPOP (13.0%). AR alterations were more prevalent in metastatic/non-primary tumor versus primary prostate biopsy sites (70.6% [12/17] vs 43.2% [16/37]). Notably, 6 AR-V7+ prostate tumors were confirmed as hormone naive. 82.1% (23/28) of AR -altered samples harbored AR-V7 with no other detected AR alteration, while 4 samples with AR-V7 harbored additional AR DNA alterations (3 w/ AMP, 1 w/ MUT), all of which were from secondary TBx sites. Conclusions: We describe the prevalence of AR alterations in PC TBx using F1CDx, which captures AR AMP and MUT in DNA, and F1RNA, which detects AR-V7 in RNA. The high prevalence of AR-V7 in secondary TBx sites in our cohort (>70%) reflects known increased expression associated with successive lines of anti-androgen/AR therapy. However, a high prevalence of AR-V7 was also detected in primary prostate biopsies (>40% compared to a reported <1% in CTCs), including in 6 hormone naive patients, suggesting sensitivity to detect low-level abundance even in hormone sensitive PC (HSPC). While detection of AR-V7 in CTCs suggests a patient may benefit from taxane chemotherapy over an ARSi in the setting of CRPC, the clinical significance in HSPC is not well understood. Clinical validation is required to determine the utility of AR-V7 detection in TBx using F1RNA in both the CRPC and HSPC settings. A combination DNA/RNA CGP strategy reporting on the spectrum of AR resistance alterations (AMP, MUT, AR-V7), along with non- AR genomic features, has the potential to enable informed use of ARSi and other agents at key decision nodes in PC patient care.
High-power femtosecond mid-IR source with tunable center frequency and chirp
We present an experimental implementation of a chirped mid-infrared (mid-IR) high-power laser source with variable center frequency between 4 and 30 THz and continuously tunable frequency sweep of up to 20% within one pulse, with a pulse duration of 2 ps. The peak electric field obtained at 4 THz is 1.5 MV/cm. We generate the mid-IR light using a difference-frequency generation process with two phase-locked, chirped IR pulses. The obtained mid-IR electric field waveform is characterized using electro-optic sampling. We compare our experimental results with the predictions of numerical simulations. The results indicate the potential for efficient driving of vibrational modes into a strongly anharmonic regime, in cases where using Fourier-transform-limited pulses to achieve similar vibrational amplitudes would lead to dielectric breakdown.